Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25952878 | 0.91 | DRD2 (0.32) | OPRM1OPRL1 | |
| SCHEMBL25129589 | 0.89 | OPRM1 (0.35) | OPRM1OPRL1CYP2D6HRH3 | |
| SCHEMBL26351186 | 0.87 | OPRM1 (0.32) | OPRM1OPRL1 | |
| SCHEMBL20243619 | 0.87 | KAT2B (0.30) | — | |
| SCHEMBL29342935 | 0.84 | — | — | |
| SCHEMBL23482195 | 0.84 | OPRM1 (0.32) | OPRM1OPRL1 | |
| SCHEMBL24942058 | 0.83 | KDM4E (0.31) | — | |
| SCHEMBL408518 | 0.83 | DRD2 (0.36) | — | |
| SCHEMBL408514 | 0.83 | DRD2 (0.36) | — | |
| SCHEMBL17189766 | 0.83 | DRD2 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | OPRM1 4583/4885OPRL1 4262/4885CYP2D6 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.